Here are the most clinically significant terms and keywords extracted from the guideline, critical for understanding the guidance:  

### **Key Conditions & Populations**  
- **Pregnancy**  
- **Breastfeeding**  
- **Familial hypercholesterolaemia (FH)**  
- **Severe hypertriglyceridaemia**  
- **Hypertriglyceridemia**  
- **Pancreatitis (history of)**  
- **Genetic disorders (causing high triglycerides)**  
- **Dyslipidaemia in children**  

### **Key Medications & Therapies**  
- **Statins** (contraindicated in pregnancy)  
- **Ezetimibe**  
- **PCSK9 inhibitors (PCSK9i)**  
- **Bile acid sequestrants** (safe in breastfeeding)  
- **Fibrates (e.g., fenofibrate)**  
- **Omega-3 fish oils (e.g., OMACOR)**  
- **Icosapent ethyl**  

### **Key Clinical Actions & Recommendations**  
- **Specialist care (for FH in pregnancy)**  
- **Limited treatment options (for severe hypertriglyceridemia)**  
- **Counseling & referral**  
- **Maternal medicine & lipidology services involvement**  
- **Continuation of icosapent ethyl (if already on it)**  
- **High-dose omega-3 (caution advised)**  
- **Theoretical risks vs. benefits of statins in pregnancy**  

### **Key Themes**  
- **Lipid control in pregnancy**  
- **Medication safety in pregnancy/breastfeeding**  
- **Risk assessment & multidisciplinary care**  

These terms encapsulate the core clinical considerations for managing lipid disorders in pregnancy and breastfeeding.